The Drug Check eTEN Project to validate an on-line pan-European service

The objective of the Drug Check project is to validate an on-line, pan-European service, which gathers, organises, stores, makes available and presents information and data covering pharmaceuticals and their interactions. The service provides a user-friendly, reliable, intelligent and fast mechanism to accept questions and advanced queries, process them and offer accurate answers justified with the relevant bibliography, in order to assist healthcare professionals in making the proper decisions on medication prescriptions and pharmaceutical treatments both in and out of the hospital without interrupting healthcare delivery.

The service will be offered as a web-based/mobile application to healthcare professionals and institutions (e.g. hospitals, research organisations) following the ASP (application service provider) model, and its functionality will facilitate users to gain optimum access to the service at any time, from any place using various devices (computer, mobile phones, etc), at low cost and with enhanced userfriendliness and usability, in order to become a fast, reliable, accurate and effective companion to their everyday practise. A consortium of academic experts, IT integrators and Consulting companies will offer the service via Internet and mobile platforms to healthcare professionals.

It is envisaged that the service, after its deployment, will be an invaluable companion to a wide range of healthcare professionals, by enhancing their skills and empowering their decision-making processes, thus reducing unwanted effects and improving cost-effectiveness of patients' treatment and therefore contributing to better healthcare services for all citizens.

The DrugCheck service can be a valuable tool to all healthcare professionals who want fast access to trusted and verified information (through latest bibliography and publications) about potential interactions between pharmaceuticals. The service is not limited to the information offered from the drug's documentation provided from the company but offers information on mechanisms and results of interactions between pharmaceuticals.

DrugCheck service offers the following functionality:

  • Drug Interactions: The service describes the various types of interactions between pharmaceuticals (and also nutritional elements).
  • Detailed description of the interaction mechanism and the mechanism in case of special patients groups, location of interaction, pharmacokinetic properties etc.
  • Reference to the necessity of the measurement of the levels of some of the medicines already administered or scheduled to be administered to the patient, in order to decide the right dose of the medicine to minimise the risk of potential interactions
  • Effect of interaction and management of effects
  • References to source of knowledge (bibliography) and links to documentation.

For further information, please visit:
http://www.drug-check.org

Most Popular Now

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...